5 Tips from Our Partners' Analysis
InMode is a medical aesthetic treatment company with excellent financials
Medical aesthetic treatments are an exciting industry, and with good business management, it can breed lucrative stocks.
Our partners Brian Feroldi and Brian Stoffel used Stock Card, SEC filings, and more to analyze InMode (INMD) stock!
Here are 5️⃣ great tips they shared:
1️⃣ The sales side of this company is very successful, marketing directly to medical aesthetic practices. The direct approach and involvement (50% of the employees are hired for sales) keep profits rolling in!
2️⃣ The sales growth section of the INMD stock card shows a 3-year compound growth rate of 56.8%! This is a very high rate to maintain for years in a row. Not shown here is the Gross Profit Margin of 85%, as well. 👀
3️⃣ Traditionally, medical aesthetics were made using harsh lasers and did not hold it’s longevity. InMode’s products are a new generation of non-invasive and longer-lasting treatments that are disruptive and modern.
4️⃣ InMode is looking for ways to increase profits from its existing customer base. The company has already begun creating these other streams of income through the sales of warranties and consumables like one-time use tips, etc.
5️⃣ Although INMD outsources its manufacturing, it has landed long-term agreements with partners for production. The company also handles choosing the materials and tracking quality assurance itself!
Check out the full breakdown:
BONUS PARTNER PORTFOLIO
Follow the Quality Checklist portfolio for the highest-rated stocks they analyze
💥 Bonus 💥 InMode stock made it on to Brian Feroldi’s Quality Checklist Portfolio! Both Brians use Stock Card to research and hold themselves accountable with their highest conviction picks. Follow it here to know about his next updates! ⬇️